GMED vs MDT: Which Is the Better Buy in 2026?
Last updated November 2026
Short answer
MDT is the larger of the two ($129.16B market cap): the incumbent the market prices for continued execution (15.76x forward earnings, beta 0.57). GMED is the smaller challenger ($9.91B), priced similarly on forward earnings (13.99x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.
GMED vs MDT: the tie-breaker metrics
Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | GMED | MDT | What it tells you |
|---|---|---|---|
| Market cap | $9.91B | $129.16B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 13.99 | 15.76 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Trailing P/E | 18.39 | 24.81 | Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price. |
| Beta | 0.95 | 0.57 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 14% of range | 84% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 2.07 | 2.57 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Before you buy: how GMED and MDT affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. GMED and MDT share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined GMED and MDT exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Globus Medical (GMED) do?
Globus Medical designs and sells musculoskeletal implants and the enabling technology used to place them. The core business is spine: pedicle screws, interbody cages, cervical plates, expandable implants and the disposable instruments that go with them, sold to hospitals and surgery centers largely through a direct sales force. Sitting on top of that is the enabling-technology line, principally the ExcelsiusGPS robotic navigation platform, the Excelsius3D imaging system and the Excelsius Flex robot aimed at knee replacement. The robots themselves are a modest share of revenue; their commercial purpose is to place capital in a hospital and pull recurring implant volume through it for years afterward. The September 2023 all-stock merger with NuVasive roughly doubled the company's size and made it the second largest spine business in the world behind Medtronic, and the April 2025 acquisition of Nevro added spinal cord stimulation for chronic pain, extending Globus beyond surgical implants into neuromodulation.
What does Medtronic (MDT) do?
Medtronic is one of the largest medical device companies in the world, designing, manufacturing, and selling therapies and devices across a broad range of chronic and acute conditions. Its business spans three main areas after October 2026: Cardiovascular (pacemakers, defibrillators, heart valves, and cardiac ablation), Neuroscience (spine implants, neuromodulation for pain and movement disorders, and surgical navigation), and Medical Surgical (surgical stapling, energy devices, and a growing robotic-surgery platform). Its former Diabetes unit (insulin pumps and continuous glucose monitoring) was carved out as MiniMed, which listed on Nasdaq under MMED; on October 15, 2026 Medtronic exchanged its remaining 252.8 million MiniMed shares for Medtronic shares in an exchange offer that was 5.4 times subscribed, so it no longer owns any of MiniMed. The company sells primarily to hospitals, surgeons, and health systems, generating durable, recurring demand tied to procedure volumes and chronic-disease management. Medtronic's scale gives it deep relationships with providers, a large installed base of devices, and the resources to fund extensive R&D and acquisitions. Growth depends on new product cycles, pipeline approvals, and global expansion, especially in emerging markets. Founded in 1949 and headquartered in Ireland for tax purposes (operationally rooted in Minnesota), Medtronic is a large-cap, dividend-growing medical-technology company tied to long-term healthcare demand and aging demographics, with trailing revenue of about $37.5 billion as of October 2026.
GMED vs MDT: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- GMED drivers: NuVasive integration and operating leverage; Robotics as an implant channel.
- MDT drivers: Diversified device portfolio; Innovation pipeline and new product cycles.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: The largest structural risk is pricing: spinal implants face steady per-unit price erosion from hospital purchasing groups and payers, so Globus has to grow procedure volume just to hold revenue flat. For MDT, medtronic has at times delivered sluggish organic growth, raising concerns that its scale slows innovation relative to nimbler competitors like Boston Scientific and Edwards Lifesciences.
GMED or MDT: which should you pick?
Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick GMED if you believe its drivers more; MDT if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the GMED and MDT guides.
GMED vs MDT: the full fundamentals
GMED. At roughly $77.94 a share against 2026 consensus non-GAAP EPS of about $5.00 and 2027 consensus near $5.40, Globus trades around 14 to 16 times forward earnings and about 3.3 times trailing revenue, a discount to large-cap medtech peers. The shares have fallen about 11% in 2026 despite four consecutive earnings beats, which suggests the market is discounting slowing revenue growth and the Nevro drag more than it is rewarding margin expansion. The balance sheet is light, with about $595 million of cash against roughly $112 million of debt.
MDT. At about $95 on October 16, 2026, Medtronic trades near 15 times forward earnings, a moderate multiple next to faster-growing medtech peers, while the GAAP trailing P/E of about 23x includes acquisition amortization. The 25 analysts tracked by Yahoo Finance hold a mean target near $104. The next report, expected around November 17, 2026, will be the first read on the company after the MiniMed exit, with consensus at about $1.33 of EPS on $9.5 billion of revenue.
Headline figures (approximate, October 2026): GMED shows revenue (ttm) ~$3.14 billion, q2 2026 revenue ~$789.6 million, up ~6% year over year (~9% excluding Nevro), margins (ttm) ~69% gross, ~25% operating, ~17% net, eps ~$3.90 GAAP trailing; Q2 2026 non-GAAP ~$1.34 vs ~$1.10 estimate; MDT shows revenue (ttm) ~$37.5 billion, up ~14% year over year in the July 2026 quarter, margins ~65% gross, ~19% operating, ~14% net, net income (ttm) ~$5.2 billion, eps ~$4.07 GAAP trailing; ~$6.41 forward estimate.
The bottom line: GMED vs MDT
GMED and MDT are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined GMED and MDT exposure against your real portfolio. It is not an investment adviser.
Wondering how GMED or MDT fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Globus Medical
Ask Walnut's AI anything about GMED and see how it fits what you own.
FAQ
What is the difference between GMED and MDT?
+
Globus Medical designs and sells musculoskeletal implants and the enabling technology used to place them. Medtronic is one of the largest medical device companies in the world, designing, manufacturing, and selling therapies and devices across a broad range of chronic and acute conditions. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is GMED or MDT the better stock?
+
Neither is universally better. MDT is the larger incumbent; GMED is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, GMED or MDT?
+
On forward P/E (as of November 2026), GMED trades at 13.99x and MDT at 15.76x, so GMED is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both GMED and MDT?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of GMED vs MDT?
+
GMED: The largest structural risk is pricing: spinal implants face steady per-unit price erosion from hospital purchasing groups and payers, so Globus has to grow procedure volume just to hold revenue flat. Competition is heavy on both flanks, with Medtronic and its Mazor platform on one side and fast-growing challengers such as Alphatec taking surgeon share on the other, and the surgeon-recruiting lever that drives current outperformance can run in reverse. Regulatory exposure is concrete rather than theoretical: the July 2024 FDA warning letter concerning ExcelsiusGPS complaint handling and medical device reporting is the kind of matter that can escalate to consent decrees or shipment holds if not resolved. Nevro is shrinking, and management's own recovery timeline extends into late 2026, so an impairment is possible if trial volumes stay weak. Plaintiff firms have publicly announced investigations following the 2025 revenue miss and the FDA letter, and product-liability activity around spinal cord stimulators adds separate legal cost that is hard to size in advance. MDT: Medtronic has at times delivered sluggish organic growth, raising concerns that its scale slows innovation relative to nimbler competitors like Boston Scientific and Edwards Lifesciences. The Hugo robotic platform faces an entrenched Intuitive Surgical. The MiniMed separation removes diabetes but adds near-term noise: reported results, guidance and comparisons will shift as the unit leaves the numbers, and analysts expect EPS of about $1.33 for the quarter ending October 2026, slightly below the year-earlier level. Device companies face reimbursement pressure, hospital budget constraints, FDA approval and recall risk, and litigation exposure. A large international footprint brings currency headwinds, and debt stood near $28 billion against about $8.8 billion of cash as of October 2026. The stock is roughly flat over the past year despite faster sales growth. New-product execution, pipeline timing, and the ability to sustain organic growth remain the key swing factors for the investment case.
Related comparisons
Browse all stock comparisons.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell GMED or MDT; figures are approximate and dated (as of November 2026). Verify current data before investing.